Gadofosveset trisodium is an intravenous contrast agent used during magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with peripheral vascular disease. The agent allows for the vascular system to be imaged more clearly by the MRA.
- Mechanism
- Curator reviewed
Gadofosveset binds reversibly to endogenous serum albumin resulting in longer vascular residence time than non-protein binding contrast agents. The binding to serum albumin also increases the magnetic resonance relaxivity of gadofosveset and decreases the relaxation time (Tl) of water protons resulting in an increase in signal intensity (brightness) of blood.
- Primary indication
- Gadofosveset trisodium is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.Curator reviewed · 1 structured indication
- Formula / weight
- C33H38GdN3Na5O14P · 1003.85 g/mol (avg)
- First approval
- Canada, 2007 · United States, 2008
- Also known as
- Gadofosveset
- Code names
- MS-325
- Brand names
Resolves to
XGOSYNSWSRUASG-SSMZTGFVSA-HSMILES[Na+].[Na+].[Na+].[Gd+3].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)C[C@H](COP([O-])(=O)OC1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1)N(CC([O-])=O)CC([O-])=OWhat you can answer from here — as of August 31, 2026
Which drugs share a target with Gadofosveset trisodium, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account